Health Promotion and Chronic Disease Prevention in Canada, Vol 46, No 4, April 2026
A mixed-methods approach to understanding pharmacistsâ experiences with the CANRISK diabetes risk questionnaire and user guide; Evolving influence of mental health stigma in Ontario public safety organizations: a qualitative study
Health Promotion and Chronic Disease Prevention in Canada, Vol 46, No 4, April 2026
A mixed-methods approach to understanding pharmacistsâ experiences with the CANRISK diabetes risk questionnaire and user guide; Evolving influence of mental health stigma in Ontario public safety organizations: a qualitative study
Health Promotion and Chronic Disease Prevention in Canada, Vol 46, No 3, March 2026
Natural experiments in the built environment: evaluating impacts on health; Shaping healthier futures: community-level impact of the Alberta Healthy Communities Approach
BORN Researchers to Present at the 2026 Precision Child and Youth Mental Health Conference
Monthly update to the list of new safety and effectiveness reviews for health products
The list of new safety and effectiveness reviews has been updated and now includes safety reviews initiated between February 1 and 28, 2026. The next update is scheduled for May 2026.
Guidance on how to interpret “significant change” of a medical device
Health Canada has published an updated Guidance on how to interpret significant change of a medical device. This update clarifies Health Canada’s current interpretation of what constitutes a significant change for Class III and Class IV medical devices.
Health Product InfoWatch, March 2026
Content Product Monograph update: Stivarga (regorafenib); Notice of authorization with conditions: Voxzogo (vosoritide for injection)